Navigation Links
Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
Date:8/27/2007

MENLO PARK, Calif., Aug. 27, 2007 Geron Corporation (Nasdaq: GERN) today reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction.

Published online Aug. 26 in Nature Biotechnology, the landmark study is the first to document the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the site of the infarct. In addition, the research confirms the effectiveness of a scalable production system that enables Geron to manufacture the cardiomyocytes for use in ongoing large animal studies and, ultimately, testing in humans.

The study describes the feeder- and serum-free, scalable production of hESC-derived cardiomyocytes, their survival in the infarct zone of rats when transplanted four days after infarction, and echocardiographic and MRI evidence of significant improvement in cardiac structure and contractile function. Gerons scientists conducted the study in collaboration with Charles Murry, M.D., Ph.D., and Michael Laflamme, M.D., Ph.D., at the University of Washington.

This is one of the most important publications on hESCs for Geron to date, said Thomas B. Okarma, Ph.D., M.D., Gerons president and chief executive officer. Our cardiomyocytes are the first human cardiac cells shown to survive after injection into an infarcted ventricle and to produce significant improvement in heart function. hESCs are the only cell type shown definitively to form cardiomyocytes.

Approximately 5.2 million people in the United States suffer from heart failure, and approximately 865,000 people experience myocardial infarction each year. About 36% of this population progresses to heart failure within five years of a first infarction. More than one-third of all heart failure patients die within two years of diagnosis.

Were developing our ca
'/>"/>

Contact: Sion Rogers
sion.rogers@russopartnersllc.com
212-845-4292
Russo Partners, LLC
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
2. MRSA study demonstrates need for frequent hand washing and environmental disinfection in health care settings
3. Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection
4. New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease
5. Xie Lab demonstrates the role of microRNA pathway
6. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
7. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
8. Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6
9. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
10. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
11. Vascular structure and function improve with diet and exercise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
(Date:7/24/2014)... in which life arose have been maintained in our cells ... , Research published today in the Journal of Biological ... likely also in animals still perform ancient reactions thought to ... four billion years ago. , The primordial soup theory suggests ... result of the combination of metals, gases from the atmosphere ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... COLUMBIA Taking vitamin D supplements during pregnancy is not ... preterm labor/births and infections, according to results of a randomized ... (PAS) annual meeting in Vancouver, British Columbia, Canada. ... D could cause birth defects, according to Carol L. Wagner, ...
... UniversityCorpus Christi were astounded to find that seamounts, mountains that ... common ocean habitats in the world. Their findings are published ... prevalence of seamounts, which are treasure troves of marine biodiversity. ... never see a seamount, but this study shows that they ...
... of daily diet advice? If only we knew which ... new finding by a team of Cornell University researchers, dieters ... adhere to their diet. Understandably, they also report losing ... Brian Wansink, Director of the Cornell Food and Brand Lab, ...
Cached Biology News:Researchers recommend pregnant women take 4,000 IU vitamin D a day 2Scientists identify seamounts as significant, unexplored territory 2
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) ... fostering and monetization of intellectual property, today announced that ... period ending June 30, 2014 on Monday, August 18, ... at 10 a.m. ET on Monday, August 18, 2014 ... led by the company,s CEO, Anthony Hayes . ...
(Date:7/24/2014)... 2014 The patent provides substantially ... test results. It also enables true sample ID ... and reporting of high profile assays such as ... rapidly growing area of biotechnology that includes DNA ... and companion diagnostics in personalized medicine. The new ...
(Date:7/23/2014)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today ... For the second quarter ended June ... $7.0 million, or $0.10 per share, compared to a ... for the same period in 2013. As of June ... securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University ... have succeeded in embedding nearly perfect semiconductor crystals ... of producing hybrid nanowires, very fast and multi-functional ... chip in the future. The research results will ... . , Nano-optoelectronics are considered the cornerstone of ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9A crystal wedding in the nanocosmos 2
... Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the "Company") ... ended March 31, 2010 . , ... "We have recently seen a range of ... mechanism of action and provided evidence of synergies with currently approved ...
... PARIS , May 12, 2010 , ... - New Outcomes Trial to Expand Evidence ... , ... of a multinational, randomized double-blind Phase IIIb trial,PALLAS, to assess the potential clinical benefit ...
... Scientists from Zymes LLC, the University of Windsor ... of Canada presented their research at the 2010 ... 28th .  The paper entitled, " Protection of SNpc neurons by ... disease: The role of neurotrophic factors," describes a potential treatment ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 2Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 3Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 4Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 5Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 6Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 7Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 8Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 2Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 3Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 4Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 5Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 6Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 7Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 8Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 10Zymes’ Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson’s Disease 2
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Biotin label transfer is fast emerging ... interaction discovery and confirmation. Until now, only ... targeted with label transfer reagents such as ... chain analog, Mts-Atf-LC-Biotin, are exciting additions to ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
Biology Products: